Risk factors of gastrointestinal bleeding with dabigatran etexilate for stroke prevention in atrial fibrillation patients and its preventive strategies
- 药学院－已发表论文 
新型口服直接凝血酶抑制剂达比加群酯预防卒中疗效确切,但消化道出血风险不容小视。本文结合近5年达比加群酯用于预防心房颤动患者脑卒中时致消化道出血的临床随机试验和详细个案报道,对达比加群酯致消化道出血的可能危险因素、预防达比加群酯致消化道出血的措施等作一综述。临床医师应权衡应用达比加群酯的利弊,保证治疗的安全、有效。Dabigatran etexilate, a new direct thrombin inhibitor, has precise clinical curative effect on reducing the risk of stroke in patients with atrial fibrillation, but the risk for major gastrointestinal bleeding is significant. This paper reviewed risk factors and preventive strategies of gastrointestinal bleeding with dabigatran etexilate for stroke in atrial fibrillation patients according to randomized trials and case reports in recent five years. Clinician should balance the risk of bleeding with treatment outcome of dabigatran etexilate to ensure the effectiveness and safety of treatment.